CN Patent

CN116473956A — 包含趋化因子受体通路抑制剂的组合物

Assigned to Dimerix Bioscience Pty Ltd · Expires 2023-07-25 · 3y expired

What this patent protects

本发明涉及一种组合物，其包含：i.至少一种趋化因子受体2(CCR2)通路抑制剂或其药学上可接受的盐；ii.浓度为30至70％w/w的稀释剂；iii.浓度为2至5％w/w的粘合剂；iv.浓度为2至8％w/w的崩解剂；和v.浓度为0.05至5％w/w的润滑剂。

USPTO Abstract

本发明涉及一种组合物，其包含：i.至少一种趋化因子受体2(CCR2)通路抑制剂或其药学上可接受的盐；ii.浓度为30至70％w/w的稀释剂；iii.浓度为2至5％w/w的粘合剂；iv.浓度为2至8％w/w的崩解剂；和v.浓度为0.05至5％w/w的润滑剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN116473956A
Jurisdiction
CN
Classification
—
Expires
2023-07-25
Drug substance claim
No
Drug product claim
No
Assignee
Dimerix Bioscience Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.